Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | 0.01 | 0.19 |
| FCF Yield | -281.53% | -90.77% | -257.86% | -77.94% |
| EV / EBITDA | -0.28 | -1.58 | 0.17 | -0.76 |
| Quality | ||||
| ROIC | -908.45% | -68.65% | -141.51% | -160.13% |
| Gross Margin | 63.17% | 36.78% | 10.09% | 40.41% |
| Cash Conversion Ratio | 0.62 | 0.84 | 0.97 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.63% | -44.12% | -30.83% | 38.94% |
| Free Cash Flow Growth | 0.00% | 54.12% | 24.92% | 3.01% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | -0.56 | 0.57 | 0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.20 | 0.00 | 1.52 | 3.43 |
| Cash Conversion Cycle | 76.19 | 500.44 | 191.07 | 63.71 |